ZCL278

Catalog No.S7293 Batch:S729301

Print

Technical Data

Formula

C21H19BrClN5O4S2
Molecular Weight 584.89 CAS No. 587841-73-4
Solubility (25°C)* In vitro DMSO 100 mg/mL (170.97 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 5.000mg/ml (8.55mM) Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 5.000mg/ml (8.55mM) Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description ZCL278 is a selective Cdc42 GTPase inhibitor with Kd of 11.4 μM.
Targets
Cdc42 GTPase [1]
11.4 μM(Kd)
In vitro ZCL278 inhibits Cdc42 GTPase activity by the competition with GTP and inhibits Rac/Cdc42 phosphorylation in a time-dependent manner. ZCL278 (50 μM) inhibits Cdc42-mediated microspike formation and disrupts GM130-docked Golgi structures in serum-starved Swiss 3T3 fibroblasts. In addition, ZCL278 also suppresses Cdc42-mediated neuronal branching and growth cone dynamics as well as actin-based motility and migration in a metastatic prostate cancer PC-3 cell line without cytotoxicity. [1]

Protocol (from reference)

References

  • https://pubmed.ncbi.nlm.nih.gov/23284167/

Customer Product Validation

<p>Rho GTPases were involved in NaAsO2 induced apoptosis in rat CGNs. A. Representative fluorescence images of cells exposed to 0 and 10 μM NaAsO2 for 24 h with or without ZCL278 (an inhibitor of Cdc42), or a Rac1 inhibitor NSC23766. Both ZCL278 and NSC23766 reduced the apoptotic cells. B. The graph indicates TUNEL-positive rat CGNs exposed to NaAsO2 (10 μM) with ZCL278 or NSC23766 groups decreased significantly compared with those of NaAsO2 treatment group. Data are expressed as mean ± SD from at least 5 visual fields. C. Rat CGNs in 96-well plates were treated by 0 and 10 μM NaAsO2 for 24h with or without ZCL278 (an inhibitor of Cdc42) pretreatment for 1 h, or a Rac1 inhibitor NSC23766 pretreatment for 12 h, and assessed by a CCK-8. ZCL278 and NSC23766 increased rat CGNs viability exposed to NaAsO2. All statistical results are expressed as means±SD from at least three independent experiments. ***P<0.001 vs control, # P<0.05, ##P<0.01, ###P<0.001 VS NaAsO2 treatment group.</p>

, , Cell Physiol Biochem, 2015, 36(4):1613-27.

Effect OF ZCL278 on activation of Jak1/2 and Stat3 by IL-1β. PACs were treated with IL-1β at 10 ng/ml for the indicated times or 1 h。

Data from [ , , J Bone Miner Res, 2018, 33(5):945-958 ]

(C) Survival rates of shrimp 72 h after ZCL278 injection. Shrimp injected with DMSO were used as controls. (D) WSSV IE1 expression 24 h after ZCL278 injection. Shrimp injected with a corresponding amount of DMSO were used as controls. All results shown are means and SD for experiments repeated at least 3 times; the data were statistically analyzed using the Student t test. *, P < 0.05; **, P < 0.01.

Data from [ , , J Virol, 2017, 91(5) ]

Effects of ZCL278 treatment on the actin polymerization in porcine oocyte. MII oocytes were labeled with phalloidin to visualize actin (green) and counterstained with PI for chromosomes (red). (a) Representative confocal images show actin distribution in control (i) and ZCL278-treated (ii,iii) oocytes. Arrows indicate the defective polymerization of actin. Scale bars, 20 μm. (b) Quantitative analysis of abnormal actin distribution in control (n = 47) and ZCL278‐treated oocytes (n = 52). Each group and data are expressed as means ± SD. *p < 0.05 versus controls. MII: metaphase II; SD: standard deviation.

Data from [ , , J Cell Physiol, 2018, doi:10.1002/jcp.27510 ]

Selleck's ZCL278 Has Been Cited by 16 Publications

Cdc42 is crucial for the early regulation of hepatic stellate cell activation [ Am J Physiol Cell Physiol, 2025, 10.1152/ajpcell.00987.2024] PubMed: 39871537
GEFT inhibits the GSDM-mediated proptosis signalling pathway, promoting the progression and drug resistance of rhabdomyosarcoma [ Cell Death Dis, 2024, 15(11):867] PubMed: 39616223
Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer [ Cancer Commun (Lond), 2023, 43(8):909-937] PubMed: 37434399
ARHGEF37 overexpression promotes extravasation and metastasis of hepatocellular carcinoma via directly activating Cdc42 [ J Exp Clin Cancer Res, 2022, 41(1):230] PubMed: 35869555
GEFT Inhibits Autophagy and Apoptosis in Rhabdomyosarcoma via Activation of the Rac1/Cdc42-mTOR Signaling Pathway [ Front Oncol, 2021, 11:656608] PubMed: 34221974
NecroX-5 Can Suppress Melanoma Metastasis by Reducing the Expression of Rho-Family GTPases [ J Clin Med, 2021, 10(13)2790] PubMed: 34201921
Epigenetically upregulated GEFT-derived invasion and metastasis of rhabdomyosarcoma via epithelial mesenchymal transition promoted by the Rac1/Cdc42-PAK signalling pathway. [ EBioMedicine, 2019, 50:122-134] PubMed: 31761617
Cdc42 Is Essential for Both Articular Cartilage Degeneration and Subchondral Bone Deterioration in Experimental Osteoarthritis [Hu X J Bone Miner Res, 2018, 33(5):945-958] PubMed: 29314205
Intersectin-Cdc42 interaction is required for orderly meiosis in porcine oocytes [Li X J Cell Physiol, 2018, 10.1002/jcp.27510] PubMed: 30478952
CDC42 controls the activation of primordial follicles by regulating PI3K signaling in mouse oocytes [ BMC Biol, 2018, 16(1):73] PubMed: 29976179

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.